Promising Results from Spinogenix's Phase 2 Trial of Tazbentetol for Schizophrenia Show Safety and Efficacy Spinogenix's Phase 2 trial data reveals early improvements in treating schizophrenia with Tazbentetol, highlighting safety and symptom reduction.

Promising Results from Spinogenix's Phase 2 Trial of Tazbentetol for Schizophrenia Show Safety and Efficacy #United_States #Los_Angeles #schizophrenia #Spinogenix #Tazbentetol

Spinogenix Concludes Patient Enrollment for Groundbreaking Schizophrenia Treatment Trial Spinogenix has successfully concluded patient enrollment for its Phase 2 trial of Tazbentetol, a novel treatment for schizophrenia, aiming to improve cognitive and negative symptoms.

Spinogenix Concludes Patient Enrollment for Groundbreaking Schizophrenia Treatment Trial #None #schizophrenia #Spinogenix #Tazbentetol

Spinogenix Supports FRAXA Foundation in Pioneering Trial Against Fragile X Syndrome Spinogenix announces collaboration with FRAXA Research Foundation to advance Phase 2b trial of SPG601, aimed at treating Fragile X Syndrome.

Spinogenix Supports FRAXA Foundation in Pioneering Trial Against Fragile X Syndrome #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601

Spinogenix's Tazbentetol Shows Promise as Cognitive Therapy for Alzheimer's Disease Spinogenix's Phase 2a trial reveals Tazbentetol's potential in improving cognitive function in Alzheimer's patients, showing notable safety and efficacy.

Spinogenix's Tazbentetol Shows Promise as Cognitive Therapy for Alzheimer's Disease #USA #Los_Angeles #Alzheimer's #Spinogenix #Tazbentetol

Spinogenix Achieves WHO Approval for Tazbentetol, a Groundbreaking Alzheimer's Therapy Spinogenix, Inc. has announced that the WHO approved 'tazbentetol' as the non-proprietary name for its innovative therapy aimed at neurodegenerative conditions.

Spinogenix Achieves WHO Approval for Tazbentetol, a Groundbreaking Alzheimer's Therapy #USA #Los_Angeles #Alzheimer's #Spinogenix #Tazbentetol

Spinogenix Reveals Promising Phase 2a Results for SPG302, Innovative ALS Treatment Spinogenix announces encouraging topline results from its Phase 2a trial of SPG302, a groundbreaking ALS treatment, showcasing significant potential.

Spinogenix Reveals Promising Phase 2a Results for SPG302, Innovative ALS Treatment #United_States #Los_Angeles #ALS_Treatment #Spinogenix #SPG302

Spinogenix Makes Significant Strides with Phase 2a Trial Results for Groundbreaking Fragile X Treatment at AACAP Spinogenix reveals full Phase 2a trial results for SPG601, a pioneering treatment for Fragile X Syndrome, showcasing promising cognitive improvements.

Spinogenix Makes Significant Strides with Phase 2a Trial Results for Groundbreaking Fragile X Treatment at AACAP #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601

Spinogenix's Latest Study Reveals SPG302 as a Breakthrough Neuroprotective Treatment for Glaucoma Spinogenix has published promising results from a study highlighting the potential of SPG302 in protecting retinal cells from glaucoma. The findings illuminate a new therapeutic direction.

Spinogenix's Latest Study Reveals SPG302 as a Breakthrough Neuroprotective Treatment for Glaucoma #United_States #Los_Angeles #Spinogenix #glaucoma #SPG302

Spinogenix Receives FDA Approval for SPG601 in Fragile X Syndrome Treatment Spinogenix has achieved a significant milestone with the FDA's support for SPG601, a pioneering treatment for Fragile X syndrome, addressing crucial needs in patient care.

Spinogenix Receives FDA Approval for SPG601 in Fragile X Syndrome Treatment #USA #Los_Angeles #Spinogenix #SPG601 #Fragile_X

Spinogenix Reports Promising Results on SPG302 for Alzheimer’s Disease Treatment Spinogenix, Inc. shares positive findings from its Phase 2a trial of SPG302, a pioneering treatment for Alzheimer's disease, showcasing rapid cognitive improvement and a strong safety profile.

Spinogenix Reports Promising Results on SPG302 for Alzheimer’s Disease Treatment #United_States #Los_Angeles #Alzheimer's_Disease #Spinogenix #SPG302

Spinogenix's SPG601 Receives Orphan Drug Designation for Fragile X Syndrome Treatment Spinogenix's SPG601 has been granted orphan drug designation by the EMA for treating Fragile X Syndrome, marking a significant step in therapies for this condition.

Spinogenix's SPG601 Receives Orphan Drug Designation for Fragile X Syndrome Treatment #USA #Los_Angeles #Spinogenix #SPG601 #Fragile_X

Spinogenix Achieves Full Enrollment in SPG302 Phase 2 Trial for Alzheimer's Therapy Spinogenix has successfully completed full enrollment for its Phase 2 clinical trial of SPG302, aimed at treating Alzheimer's disease. Results will be shared soon.

Spinogenix Achieves Full Enrollment in SPG302 Phase 2 Trial for Alzheimer's Therapy #Los_Angeles #Australia #Alzheimer's_Disease #Spinogenix #SPG302

Spinogenix's SPG302: A Hopeful Treatment Breakthrough for ALS Patients Spinogenix, Inc. has received orphan drug designation from the EMA for SPG302, a promising therapeutic for ALS, aiming to restore synapses and improve patient quality of life.

Spinogenix's SPG302: A Hopeful Treatment Breakthrough for ALS Patients #United_States #Los_Angeles #ALS #Spinogenix #SPG302

Spinogenix Launches Expanded Access Program for Groundbreaking ALS Treatment SPG302 Spinogenix has announced an FDA-authorized Expanded Access Program for SPG302, a revolutionary treatment aimed at improving conditions for ALS patients, providing hope and innovative solutions.

Spinogenix Launches Expanded Access Program for Groundbreaking ALS Treatment SPG302 #United_States #Los_Angeles #ALS #Spinogenix #SPG302

Spinogenix Unveils Phase 2 Trial Enrollment for SPG302 as Revolutionary Therapy for Schizophrenia Spinogenix, Inc. has announced the commencement of Phase 2 patient enrollment for SPG302, marking a significant step in the treatment of schizophrenia through synaptic regeneration.

Spinogenix Unveils Phase 2 Trial Enrollment for SPG302 as Revolutionary Therapy for Schizophrenia #United_States #Los_Angeles #schizophrenia #Spinogenix #SPG302

Spinogenix Advances to Phase 2 Study Completion for SPG601 Targeting Fragile X Syndrome Spinogenix announces promising results from its Phase 2 study of SPG601 for treating Fragile X syndrome, showing potential to improve quality of life.

Spinogenix Advances to Phase 2 Study Completion for SPG601 Targeting Fragile X Syndrome #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601

FDA Fast Tracks Spinogenix's SPG601 for Fragile X Syndrome Treatment Amid Urgent Needs The FDA's Fast Track designation for Spinogenix's SPG601 marks significant progress in developing a treatment for Fragile X syndrome, a key cause of autism.

FDA Fast Tracks Spinogenix's SPG601 for Fragile X Syndrome Treatment Amid Urgent Needs #United_States #Los_Angeles #FDA #Spinogenix #Fragile_X_Syndrome